New combination therapy improves survival in non-small cell lung cancer

Vinod Aiyappan

Research output: Contribution to journalComment/debate

Abstract

The survival rate of patients with metastatic non-small-cell lung cancer remains poor even with chemotherapy. This randomised-controlled trial looks at the effect of monoclonal antibody against vascular endothelial growth factor (bevacizumab) in the treatment of patients with metastatic non-squamous-cell, non-small-cell-lung cancer.
Original languageEnglish
Pages (from-to)259
Number of pages1
JournalThorax
Volume62
Issue number3
Publication statusPublished - Mar 2007
Externally publishedYes

Fingerprint Dive into the research topics of 'New combination therapy improves survival in non-small cell lung cancer'. Together they form a unique fingerprint.

Cite this